Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study

Introduction Ustekinumab is an effective treatment of Crohn’s disease (CD). Real-world data addressing the efficacy and safety of ustekinumab are scarce. Aim Our aim was to assess the safety and efficacy of ustekinumab in a large national patient cohort. Methods A prospective multicenter study, in w...

Full description

Saved in:
Bibliographic Details
Published in:United European gastroenterology journal 2020-05, Vol.8 (4), p.418-424
Main Authors: Bar-Gil Shitrit, Ariella, Ben-Ya’acov, Ami, Siterman, Matan, Waterman, Matti, Hirsh, Ayal, Schwartz, Doron, Zittan, Eran, Adler, Yehonatan, Koslowsky, Benjamin, Avni-Biron, Irit, Chowers, Yehuda, Ron, Yulia, Israeli, Eran, Ungar, Bella, Yanai, Henit, Maharshak, Nitsan, Ben-Horin, Shomron, Eliakim, Rami, Dotan, Iris, Goldin, Eran, Kopylov, Uri
Format: Article
Language:English
Subjects:
Crohn’s disease
gastroenterology
IBD
inflammation
inflammatory bowel disease
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Ustekinumab is an effective treatment of Crohn’s disease (CD). Real-world data addressing the efficacy and safety of ustekinumab are scarce. Aim Our aim was to assess the safety and efficacy of ustekinumab in a large national patient cohort. Methods A prospective multicenter study, in which we followed patients with active CD treated with ustekinumab for 24 weeks. Induction dose was intravenous ranging from 260 to 520 mg, according to body weight, followed by 90 mg doses given subcutaneously every 8 weeks. Clinical response was defined as a reduction of at least 1 severity category, as defined by Harvey–Bradshaw index (HBI). Patients with HBI 
ISSN:2050-6406
2050-6414
DOI:10.1177/2050640620902956